China-based biopharmaceutical and biotechnology company Antengene announces its collaboration with artificial intelligence drug discovery platform developer MindRank to advance the development of difficult-to-drug molecular targets.
The collaboration is a long-term strategic partnership that would enable the companies to jointly conduct research and develop small molecule oncology drugs using best-in-class artificial intelligence technologies. Both the companies had collaborated earlier for the development of preclinical stage drug candidates.
With this partnership, Antegene plans to use MindRank’s Molecule Pro and Molecule Dance artificial intelligence platform for discovering and developing the highest quality drug candidates. Antegene has by far developed thirteen clinical and preclinical drug assets.
The Founder, Chairman, and CEO of Antegene, Dr. Jay Mei, said, “We are excited about this ground-breaking partnership with MindRank AI, established to accelerate our development of new therapies for difficult-to-drug targets. Antengene has built a pipeline of 13 assets over the past four years through both partnerships and in-house discovery.”
He further mentioned that he believes this partnership between the two industry leaders will enhance their in-house discovery capabilities and will be able to deliver effective therapeutics to patients across the globe.
Antegene was founded in Shanghai by Mei in the year 2016 and has received a total funding of $238 million in three rounds from Hillhouse Capital Group, Qiming Venture Partners, Boyu Capital, and many more. The firm specializes in developing and providing anti-cancer treatment to patients in Asia.
The founder and CEO of MindRank, Zhangming Niu, said, “We are very honored to be a strategic partner of Antengene, an industry-leader with robust R&D capabilities and a management team possessing experience in developing and commercializing some of the world’s best selling oncology drugs.”
He also added that this synergistic collaboration would enable them to develop more first-in-class oncology drugs for patients across the world.